In addition to China, AMDL believes both products will be good candidates for export to the North American and European markets.
According to Gary Dreher, chief executive officer of AMDL, "With the popularity of the Goodnak brand in China, combined with JPI's ability to sell through pre-approved distribution channels, we anticipate sales to exceed well beyond our initial annual sales forecast for Goodnak of $24 million.
Additionally, AMDL has patents and patents pending claiming novel animal models and methods for using these.
Potential products in the multi-billion dollar global cancer market are being sought by major pharmaceutical and other companies and we believe our therapy has significant, important features to offer to these firms," said Gary Dreher, AMDL President and CEO.
AMDL is a theranostics company, meaning it is involved both in the treatment of cancer, with the CIT therapy, and in its detection, with the DR-70(R) cancer blood test kit.